Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-30 @ 3:44 AM
Study NCT ID:
NCT00430092
Status:
COMPLETED
Last Update Posted:
2009-07-02
First Post:
2007-01-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
Sponsor:
Sirion Therapeutics, Inc.
Organization:
Study Overview
Official Title:
A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: